No headlines found.
Globe Newswire (Tue, 2-Dec 8:00 AM ET)
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
Globe Newswire (Mon, 24-Nov 8:00 AM ET)
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Globe Newswire (Thu, 20-Nov 8:00 AM ET)
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
Chemomab Therapeutics Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol CMMB.
As of February 2, 2026, CMMB stock price climbed to $1.67 with 46,437 million shares trading.
CMMB has a beta of 1.10, meaning it tends to be more sensitive to market movements. CMMB has a correlation of 0.10 to the broad based SPY ETF.
CMMB has a market cap of $31.49 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CMMB traded as high as $10.80 and as low as $1.53.
CMMB has underperformed the market in the last year with a return of -79.5%, while the SPY ETF gained +16.1%. In the last 3 month period, CMMB fell short of the market, returning -44.0%, while SPY returned +2.6%. However, in the most recent 2 weeks CMMB has outperformed the stock market by returning +0.6%, while SPY returned +0.5%.
CMMB support price is $1.46 and resistance is $1.64 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMMB shares will trade within this expected range on the day.